Nathan Petty
YOU?
Author Swipe
View article: Supplementary Figure 2 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 2 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 297K, Survival outcomes in Total Therapy 2 according to randomization to control arm (-T) or thalidomide (+T).
View article: Supplementary Figure 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 256K, Thalidomide effect on overall and progression-free survival according to glucocorticoid receptor (NR3C1) expression level.
View article: Supplementary Figure 1 from Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Supplementary Figure 1 from Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma Open
A. The distribution of TLG by molecular subgroup. The table shows the percentages and numbers of patients in each group. The Kruskal-Wallis p-value = 0.0135 indicates there is some difference in TLG among the subgroups. B. PFS (left) and O…
View article: Data from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Data from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
Purpose: Because dexamethasone remains a key component of myeloma therapy, we wished to examine the impact of baseline and relapse expression levels of the glucocorticoid receptor gene NR3C1 on survival outcomes in the context of treatment…
View article: Supplementary Figure 1 from Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Supplementary Figure 1 from Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma Open
A. The distribution of TLG by molecular subgroup. The table shows the percentages and numbers of patients in each group. The Kruskal-Wallis p-value = 0.0135 indicates there is some difference in TLG among the subgroups. B. PFS (left) and O…
View article: Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 142K, Effect of cumulative thalidomide dosing prior to start of maintence on OS and PFS, landmarked at start of maintence, for all patients.
View article: Supplementary Figure 5 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 5 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 94K, Post-relapse survival according to NR3C1 levels at baseline and at relapse.
View article: Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 56K, Salvage Regimen for 255 Patients with available data.
View article: Supplementary Figure/Table Legend from Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Supplementary Figure/Table Legend from Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma Open
Supplementary Figure/Table Legend
View article: Supplementary Figure Legend from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure Legend from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 88K.
View article: Supplementary Table 1 from Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Supplementary Table 1 from Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma Open
Baseline Characteristics of TT3a in Current and Omitted data
View article: Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants Open
Supplementary Table 1: Total Therapy 4 (TT4) protocol schema Supplementary Table 2: Adverse Events by Arm and Maximum NCI CTC Grade Supplementary Table 3: Top 51 gene probes distinguishing multiple myeloma with and without cytogenetic abno…
View article: Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants Open
Supplementary Figure 1: Consort flow diagram of patient flow through TT4 arms Supplementary Figure 2: Cumulative Incidence of Death and Post-Relapse Survival (P-values for S-TT4 vs L-TT4; TRM, p = 0.61; MRM, p = 0.70; OIM, p = 0.25). Suppl…
View article: Supplementary Figure Legend from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure Legend from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 88K.
View article: Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants Open
Supplementary Figure 1: Consort flow diagram of patient flow through TT4 arms Supplementary Figure 2: Cumulative Incidence of Death and Post-Relapse Survival (P-values for S-TT4 vs L-TT4; TRM, p = 0.61; MRM, p = 0.70; OIM, p = 0.25). Suppl…
View article: Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants Open
Purpose: To determine whether a reduction in the intensity of Total Therapy (TT) reduces toxicity and maintains efficacy.Experimental Design: A total of 289 patients with gene expression profiling (GEP70)-defined low-risk multiple myeloma …
View article: Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 142K, Effect of cumulative thalidomide dosing prior to start of maintence on OS and PFS, landmarked at start of maintence, for all patients.
View article: Data from Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Data from Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma Open
Purpose: Fluorine-18 fluorodeoxyglucose positron emission tomography with CT attenuation correction (18F-FDG PET/CT) is useful in the detection and enumeration of focal lesions and in semiquantitative characterization of metabolic activity…
View article: Supplementary Figure 4 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 4 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 136K, Kaplan-Meier plots for overall survival from start of first salvage therapy.
View article: Data from Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Data from Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma Open
Purpose: Fluorine-18 fluorodeoxyglucose positron emission tomography with CT attenuation correction (18F-FDG PET/CT) is useful in the detection and enumeration of focal lesions and in semiquantitative characterization of metabolic activity…
View article: Supplementary Figure/Table Legend from Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Supplementary Figure/Table Legend from Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma Open
Supplementary Figure/Table Legend
View article: Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants Open
Purpose: To determine whether a reduction in the intensity of Total Therapy (TT) reduces toxicity and maintains efficacy.Experimental Design: A total of 289 patients with gene expression profiling (GEP70)-defined low-risk multiple myeloma …
View article: Supplementary Table 1 from Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Supplementary Table 1 from Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma Open
Baseline Characteristics of TT3a in Current and Omitted data
View article: Supplementary Figure 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 256K, Thalidomide effect on overall and progression-free survival according to glucocorticoid receptor (NR3C1) expression level.
View article: Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants Open
Supplementary Table 1: Total Therapy 4 (TT4) protocol schema Supplementary Table 2: Adverse Events by Arm and Maximum NCI CTC Grade Supplementary Table 3: Top 51 gene probes distinguishing multiple myeloma with and without cytogenetic abno…
View article: Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 56K, Salvage Regimen for 255 Patients with available data.
View article: Data from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Data from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
Purpose: Because dexamethasone remains a key component of myeloma therapy, we wished to examine the impact of baseline and relapse expression levels of the glucocorticoid receptor gene NR3C1 on survival outcomes in the context of treatment…
View article: Supplementary Figure 4 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 4 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 136K, Kaplan-Meier plots for overall survival from start of first salvage therapy.
View article: Supplementary Figure 5 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 5 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 94K, Post-relapse survival according to NR3C1 levels at baseline and at relapse.
View article: Supplementary Figure 2 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 2 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 297K, Survival outcomes in Total Therapy 2 according to randomization to control arm (-T) or thalidomide (+T).